The online version of this article (doi:10.1186/1475-2875-11-79) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
AD participated in the design of the study, collected data, coordinated the study, performed statistical analysis and wrote the first draft of the manuscript. ABT, AO, ATK, MT, DD, AST and BSS participated in the design of the study, coordinated and participated in the drafting of the manuscript. IN and IS participated in the lab work and data interpretation. All the authors read and approved the final version.
Patient immune status is thought to affect the efficacy of anti-malarial chemotherapy. This is a subject of some importance, since evidence of immunity-related interactions may influence our use of chemotherapy in populations with drug resistance, as well as assessment of the value of suboptimal vaccines. The study aim was to investigate relationship between antibodies and anti-malarial drug treatment outcomes.
Some 248 children aged 0.5 and 15 years were recruited prior to the high malaria transmission season. Venous blood (5 ml) was obtained from each child to measure antibody levels to selected malaria antigens, using ELISA. Blood smears were also performed to assess drug efficacy and malaria infection prevalence. Children were actively followed up to record clinical malaria cases.
IgG levels to MSP3 were always higher in the successfully treated group than in the group with treatment failure. The same observation was made for GLURP but the reverse observation was noticed for MSP1-19. Cytophilic and non-cytophilic antibodies were significantly associated with protection against all three antigens, except for IgG4 to MSP1-19 and GLURP.
Acquired anti-malarial antibodies may play an important role in the efficacy of anti-malarial drugs in younger children more susceptible to the disease.
Authors’ original file for figure 112936_2011_2052_MOESM1_ESM.pdf
Garraud O, Diouf A, Holm I, Perraut R, Longacre S: Immune responses to Plasmodium falciparum-merozoite surface protein 1 (MSP1) antigen, II. Induction of parasite-specific immunoglobulin G in unsensitized human B cells after in vitro T-cell priming with MSP119. Immunology. 1999, 97: 497-505. 10.1046/j.1365-2567.1999.00804.x. PubMedCentralCrossRefPubMed
Brown GV: Progress in the development of malaria vaccines: context and constraints. Parassitologia. 1999, 41: 429-432. PubMed
Ballou WR, Kester KE, Stoute JA, Heppner DG: Malaria vaccines: triumphs or tribulations?. Parassitologia. 1999, 41: 403-408. PubMed
Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, Tiono AB, Konate AT, Chilengi R, Theisen M, Dodoo D, Remarque E, Bosomprah S, Milligan P, Sirima SB: Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect Immun. 2008, 76: 759-766. 10.1128/IAI.01147-07. PubMedCentralCrossRefPubMed
Nebie I, Tiono AB, Diallo DA, Samandoulougou S, Diarra A, Konate AT, Cuzin-Ouattara N, Theisen M, Corradin G, Cousens S, Ouattara AS, Ilboudo-Sanogo E, Sirima BS: Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria?. Trop Med Int Health. 2008, 13: 229-237. 10.1111/j.1365-3156.2007.01994.x. CrossRefPubMed
OMS: Évaluation et surveillance de l'efficacité des antipaludiques pour le traitement à P. falciparum non compliqué. 2003, Genève: OMS/RBM/HTM/200350
Lusingu JP, Vestergaard LS, Alifrangis M, Mmbando BP, Theisen M, Kitua AY, Lemnge MM, Theander TG: Cytophilic antibodies to Plasmodium falciparum glutamate rich protein are associated with malaria protection in an area of holoendemic transmission. Malar J. 2005, 4: 48-10.1186/1475-2875-4-48. PubMedCentralCrossRefPubMed
Gansané ANI, Soulama I, Tiono A, Diarra A, Konaté AT, Ouédraogo A, Sirima BS: Change of antimalarial first line treatment in Burkina Faso in 2005. Bull Soc Path Exot. 2005, 102: 31-35. CrossRef
Bharti PK, Alam MT, Boxer R, Shukla MM, Gautam SP, Sharma YD, Singh N: Therapeutic efficacy of chloroquine and sequence variation in pfcrt gene among patients with falciparum malaria in central India. Trop Med Int Health. 2010, 15: 33-40. PubMed
WHO: Guideline for treatment of malaria. 2006, Geneva: World Health Organization
WHO: Malaria site: drug resistance. 2006, Geneva: World Health Organization
Yorke W, Macfie JWS: Observations on malaria made during treatment of general paralysis. Trans R Soc Trop Med Hyg. 1924, 18: 13-34. 10.1016/S0035-9203(24)90664-X. CrossRef
Mayxay M, Chotivanich K, Pukrittayakamee S, Newton P, Looareesuwan S, White NJ: Contribution of humoral immunity to the therapeutic response in falciparum malaria. Am J Trop Med Hyg. 2001, 65: 918-923. PubMed
Bonnet S, Petres S, Holm I, Fontaine T, Rosario S, Roth C, Longacre S: Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate. Vaccine. 2006, 24: 5997-6008. 10.1016/j.vaccine.2006.04.069. CrossRefPubMed
Wahlgren M, Perlmann H, Berzins K, Bjorkman A, Larsson A, Ljungstrom I, Patarroy ME, Perlmann P: Characterization of the humoral immune response in Plasmodium falciparum malaria. III. Factors influencing the coexpression of antibody isotypes (IgM and IgG-1 to 4). Clin Exp Immunol. 1986, 63: 343-353. PubMedCentralPubMed
McGregor IA, Carrington SP, Cohen S: Treatment of East African Plasmodium falciparum with West African human gammaglobulin. Trans R Soc Trop Med Hyg. 1963, 57: 170-175. 10.1016/0035-9203(63)90058-0. CrossRef
- Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso
Sodiomon B Sirima
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II